Jubilant Pharmova Ltd - Stock Valuation and Financial Performance

BSE: 530019 | NSE: JUBLPHARMA | Pharmaceuticals & Drugs | Small Cap

Jubilant Pharmova Share Price

1,220.50 87.15 7.69%
as on 31-Oct'24 16:01

DeciZen - make an informed investing decision on Jubilant Pharmova

Overall Rating
Bole Toh

1. Quality

2. Valuation

Overvalued

3. Price Trend

Jubilant Pharmova stock performance -

mw4me loader
P/E Ratio (SA):
635.21
Market Cap:
19,310.5 Cr.
52-wk low:
370.8
52-wk high:
1,247

Is Jubilant Pharmova Ltd an attractive stock to invest in?

1. Is Jubilant Pharmova Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Jubilant Pharmova Ltd is a average quality company.

2. Is Jubilant Pharmova Ltd undervalued or overvalued?

The key valuation ratios of Jubilant Pharmova Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

3. Is Jubilant Pharmova Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Jubilant Pharmova Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

10 Year X-Ray of Jubilant Pharmova:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Jubilant Pharmova Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation

Value Creation Index Colour Code Guide

Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24TTM
ROCE % 10.4%7.1%7.6%13.6%8.1%10.1%11.8%4.4%3.7%2.6%-
Value Creation
Index
-0.3-0.5-0.40.0-0.4-0.3-0.1-0.7-0.7-0.8-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 3,1762,6562,4913,3063,4393,1402,710726810785697
Sales YoY Gr.--16.4%-6.2%32.7%4%-8.7%-13.7%-73.2%11.6%-3.1%-
Adj EPS 1.24.84.816.110.320.613.55.13.121.9
YoY Gr.-289.4%0.2%234.6%-35.7%99.4%-34.6%-62%-39.8%-33.8%-
BVPS (₹) 122.1126.3128.2141.2146.9163.780.5153.1151.6148.6144.3
Adj Net
Profit
19.676.476.425616532821581.649.132.530
Cash Flow from Ops. 286164419558182317608-3.6-65.1143-
Debt/CF from Ops. 8114.12.69.46.20.8-49-4.62.4-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales -14.4%-25.6%-33.8%-3.1%
Adj EPS 5.8%-27.7%-46.7%-33.8%
BVPS2.2%0.2%22.7%-2%
Share Price 23.8% 17.5% 25.9% 223.3%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24TTM
Return on
Equity %
1.13.93.811.97.213.3114.421.41.3
Op. Profit
Mgn %
8.911.91316.41012.115.81.10.42.31
Net Profit
Mgn %
0.62.93.17.74.810.57.911.26.14.14.4
Debt to
Equity
1.20.90.80.60.70.80.40.10.10.20.1
Working Cap
Days
216195154133139161102139250262123
Cash Conv.
Cycle
474044232841246713614246

Recent Performance Summary

No data to display

Return on Equity has declined versus last 3 years average to 1.30%

Sales growth has been subdued in last 3 years -33.84%

Net Profit has been subdued in last 3 years -46.71%

Sales growth is not so good in last 4 quarters at -5.73%

Latest Financials - Jubilant Pharmova Ltd.

Standalone Consolidated
TTM EPS (₹) 1.9 37.2
TTM Sales (₹ Cr.) 697 6,874
BVPS (₹.) 144.3 373
Reserves (₹ Cr.) 2,283 5,925
P/BV 8.40 3.25
PE 635.21 32.56
From the Market
52 Week Low / High (₹) 370.80 / 1247.00
All Time Low / High (₹) 3.51 / 1247.00
Market Cap (₹ Cr.) 19,310
Equity (₹ Cr.) 15.9
Face Value (₹) 1
Industry PE 46.8

Management X-Ray of Jubilant Pharmova:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Jubilant Pharmova

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Sales3,1762,6562,4913,3063,4393,1402,709726810785
Operating Expenses 2,8942,3442,1732,7673,1182,7692,282719807768
Manufacturing Costs573513475568617640499103125129
Material Costs1,9361,4531,3101,7712,0531,6841,450332415356
Employee Cost 241216226264266265221164167190
Other Costs 14516216216318317911312110094
Operating Profit 2823123185393213714276317
Operating Profit Margin (%) 8.9%11.8%12.8%16.3%9.3%11.8%15.8%0.9%0.4%2.1%
Other Income 1066252467817348126138103
Interest 233201174135129136102111930
Depreciation 10787818386107100374348
Exceptional Items 1980000-20000
Profit Before Tax 24686115368183299273857942
Tax 41133510436-225942910
Profit After Tax 2057379263148321214805032
PAT Margin (%) 6.5%2.7%3.2%8.0%4.3%10.2%7.9%11.1%6.2%4.0%
Adjusted EPS (₹)12.94.65.016.59.320.213.55.13.12.0
Dividend Payout Ratio (%)23%65%60%18%49%25%37%99%159%252%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24

Equity and Liabilities

Shareholders Fund 1,9452,0142,0422,2492,3402,6071,2822,4392,4112,362
Share Capital 16161616161616161616
Reserves 1,9291,9982,0262,2332,3242,5911,2672,4232,3952,346
Minority Interest0000000000
Debt2,0801,5691,5641,2501,6021,951493174302340
Long Term Debt1,7391,1151,3871,0591,1401,328420174174247
Short Term Debt34045417719146362373012894
Trade Payables50836448774959661916159164148
Others Liabilities 7093592883763252575389115129
Total Liabilities 5,2414,3064,3824,6254,8645,4331,8452,8602,9912,980

Fixed Assets

Gross Block2,3031,5021,5871,6851,8222,2881498679471,009
Accumulated Depreciation8578616624733142422230260297
Net Fixed Assets1,4461,4151,4211,4381,4911,865127637687711
CWIP 203665115284590354737
Investments 1,7661,7091,7101,7061,7641,7641,6461,6461,6571,657
Inventories5164754545864926560323314251
Trade Receivables3193413864944814250131189194
Cash Equivalents 1374177383525840231136
Others Assets1,03728826924831740631668794
Total Assets 5,2414,3064,3824,6254,8645,4331,8452,8602,9912,980

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Cash Flow From Operating Activity 286164419558182317608-4-65143
PBT 24686115368183299273857942
Adjustment 59260230207159103196-49-3548
Changes in Working Capital 18-1688042-112-65181-3-9266
Tax Paid -38-14-5-58-49-20-43-19-17-12
Cash Flow From Investing Activity 1,319522-43-127-285-1981789331-40
Capex -79-68-103-141-281-197-92-37-59-67
Net Investments 90641300001290-9-7
Others 4921776014-4-11421309934
Cash Flow From Financing Activity -1,647-784-338-47085-41-782-10723-78
Net Proceeds from Shares 0000000000
Net Proceeds from Borrowing -301-520-156-2860-160-13600100
Interest Paid -245-201-170-138-134-147-102-11-18-30
Dividend Paid -54-51-53-55-56-153-1-80-80-80
Others -1,048-13419275419-542-16121-68
Net Cash Flow -42-9838-40-18785-18-1225
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Ratios
ROE (%)11.153.693.912.286.4312.9811.034.332.061.32
ROCE (%)10.357.137.6413.578.110.111.824.363.672.64
Asset Turnover Ratio0.560.580.60.740.720.610.740.310.280.26
PAT to CFO Conversion(x)1.42.255.32.121.230.992.84-0.05-1.34.47
Working Capital Days
Receivable Days4743514852530667289
Inventory Days6865655757670163143131
Payable Days1041101191271201328096142161

Jubilant Pharmova Ltd Stock News

Jubilant Pharmova Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Jubilant Pharmova on 31-Oct-2024 16:01 is ₹1,220.5.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 31-Oct-2024 16:01 the market cap of Jubilant Pharmova stood at ₹19,310.5.
The latest P/E ratio of Jubilant Pharmova as of 31-Oct-2024 16:01 is 635.2.
The latest P/B ratio of Jubilant Pharmova as of 31-Oct-2024 16:01 is 8.40.
The 52-week high of Jubilant Pharmova is ₹1,247 and the 52-week low is ₹370.8.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Jubilant Pharmova is ₹697.2 ( Cr.) .

About Jubilant Pharmova Ltd

Jubilant Life Sciences (formerly Jubilant Organosys) was incorporated in the year 1978. It’s a public limited company domiciled in India and incorporated under the provisions of Companies Act, 1956. Its shares are listed on BSE Limited and National Stock Exchange of India Limited.

The Pharmaceuticals segment, through its wholly-owned subsidiary Jubilant Pharma Limited, is engaged in manufacturing and supply of APIs, solid dosage formulations, radiopharmaceuticals, allergy therapy products and contract manufacturing of sterile injectables and non-sterile products through six USFDA approved manufacturing facilities in the US, Canada and India and a network of various radiopharmacies in the US.

The Life Science Ingredients segment is engaged in specialty intermediates, nutritional products and life science chemicals through five manufacturing facilities in India. The drug discovery solutions business is served by Jubilant Biosys and the India branded pharmaceuticals business is an Indian venture with a range of pharmaceutical offerings for the domestic market, focusing primarily on products to treat medical conditions in the field of cardiology and diabetology.

Business area of the company

Jubilant Life Sciences is an integrated global pharmaceutical and life sciences company engaged in pharmaceuticals, life science ingredients, drug discovery solutions and India branded pharmaceuticals.

Business segments

  • Pharmaceuticals
  • Life Science Ingredients
  • Drug Discovery & Development Solutions
  • India Branded Pharmaceuticals

Awards

2012

  • NDTV Profit Business Leadership Award 2012 for Corporate Social Responsibility. National Quality Excellence Award for best in Class manufacturing presented by Stars of the Industry Group.CII ‘National Award for Excellence in Water Management 2012’ as ‘Water Efficient Unit’ for Gajraula Unit.
  • Economic Times - Frost & Sullivan India Manufacturing Excellence Gold Award - Process Sector for 2012. I.C.C. Award for Water Resource Management in Chemical Industry for the year 2011.

2013

  • Jubilant Life Sciences Awarded ‘Excellence Award’ by Export Promotion Bureau.
  • Jubilant Life Sciences declared winner of ‘Supply Chain Excellence Awards’ at 7th Express, Logistics & Supply Chain Leadership Awards 2013.
  • Jubilant Life Sciences receives prestigious NDTV Profit Business Leadership Award 2012 for Corporate ‘Social Responsibility’.

2014

  • Jubilant Life Sciences wins Excellence Awards at ‘India Pharma Awards’ 2014.
  • BRI Partners with Jubilant Life Sciences to Bring XylamaxTM to the South Asia Poultry Market.
  • Jubilant Life Sciences conferred with Golden Peacock Business Excellence Award-2014.
  • Jubilant Biosys and Orion Corporation Announces Unique Collaborative Discovery Program in Pain Management Area.
  • IDRI and Jubilant Chemsys Extend Research for TB Drug Discovery.
  • Jubilant Life Sciences declared winner of 'Bio Excellence Award 2014' at Bangalore India Bio 2014.
  • Jubilant Biosys Announces Expansion of Drug Discovery Alliance with Janssen Pharmaceutical.

2015

  • Jubilant Life Sciences conferred with Golden Peacock National Quality Award.
  • Jubilant Life Sciences wins ASSOCHAM’s ‘Responsible Organization Excellence’ Award 2014-15.

2016

  • Sustainability Award for Best Green Process in ‘Chemical Sector’ by ‘FICCI Chemicals & Petrochemicals Awards, 2016’.
  • Winner of two CHEMEXCIL Export Awards: Trishul Export Award 2012-13 and Gold Export Award 2011-12.
  • 16th Annual Greentech Environment Award 2015 (Gold Category), conferred under ‘Chemicals and Pharmaceutical sector’ - Gajraula plant, India.

2017

  • Social Entrepreneur of the Year (SEOY)-India Award 2017.
  • Finalists for Social Entrepreneur of the Year (SEOY) India 2017 Award.
  • ‘Second Awards’ under the category of Basic Inorganic, Organic Chemicals including Agro Chemicals for the outstanding export performance of the year 2015-16 by CHEMEXCIL.
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.